Literature DB >> 23818640

Modulation of B-cell exosome proteins by gamma herpesvirus infection.

David G Meckes1, Harsha P Gunawardena, Robert M Dekroon, Phillip R Heaton, Rachel H Edwards, Sezgin Ozgur, Jack D Griffith, Blossom Damania, Nancy Raab-Traub.   

Abstract

The human gamma herpesviruses, Kaposi sarcoma-associated virus (KSHV) and EBV, are associated with multiple cancers. Recent evidence suggests that EBV and possibly other viruses can manipulate the tumor microenvironment through the secretion of specific viral and cellular components into exosomes, small endocytically derived vesicles that are released from cells. Exosomes produced by EBV-infected nasopharyngeal carcinoma cells contain high levels of the viral oncogene latent membrane protein 1 and viral microRNAs that activate critical signaling pathways in recipient cells. In this study, to determine the effects of EBV and KSHV on exosome content, quantitative proteomics techniques were performed on exosomes purified from 11 B-cell lines that are uninfected, infected with EBV or with KSHV, or infected with both viruses. Using mass spectrometry, 871 proteins were identified, of which ∼360 were unique to the viral exosomes. Analysis by 2D difference gel electrophoresis and spectral counting identified multiple significant changes compared with the uninfected control cells and between viral groups. These data predict that both EBV and KSHV exosomes likely modulate cell death and survival, ribosome function, protein synthesis, and mammalian target of rapamycin signaling. Distinct viral-specific effects on exosomes suggest that KSHV exosomes would affect cellular metabolism, whereas EBV exosomes would activate cellular signaling mediated through integrins, actin, IFN, and NFκB. The changes in exosome content identified in this study suggest ways that these oncogenic viruses modulate the tumor microenvironment and may provide diagnostic markers specific for EBV and KSHV associated malignancies.

Entities:  

Keywords:  microparticles; microvesicles; oncosomes

Mesh:

Substances:

Year:  2013        PMID: 23818640      PMCID: PMC3732930          DOI: 10.1073/pnas.1303906110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1.

Authors:  Hector Ardila-Osorio; Catherine Pioche-Durieu; Francine Puvion-Dutilleul; Bernard Clausse; Joëlle Wiels; William Miller; Nancy Raab-Traub; Pierre Busson
Journal:  Int J Cancer       Date:  2005-01-10       Impact factor: 7.396

2.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.

Authors:  Akrit Sodhi; Risa Chaisuparat; Jiadi Hu; Amanda K Ramsdell; Brendan D Manning; Edward A Sausville; Earl T Sawai; Alfredo Molinolo; J Silvio Gutkind; Silvia Montaner
Journal:  Cancer Cell       Date:  2006-08       Impact factor: 31.743

4.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes.

Authors:  B Altenberg; K O Greulich
Journal:  Genomics       Date:  2004-12       Impact factor: 5.736

5.  Cholesterol is critical for Epstein-Barr virus latent membrane protein 2A trafficking and protein stability.

Authors:  Masato Ikeda; Richard Longnecker
Journal:  Virology       Date:  2006-12-05       Impact factor: 3.616

Review 6.  Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery.

Authors:  Francesca Raimondo; Lavinia Morosi; Clizia Chinello; Fulvio Magni; Marina Pitto
Journal:  Proteomics       Date:  2011-01-17       Impact factor: 3.984

7.  Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma.

Authors:  Aadra P Bhatt; Sarah R Jacobs; Alex J Freemerman; Liza Makowski; Jeffrey C Rathmell; Dirk P Dittmer; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-29       Impact factor: 11.205

8.  Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.

Authors:  Sang-Hoon Sin; Debasmita Roy; Ling Wang; Michelle R Staudt; Farnaz D Fakhari; Dhavalkumar D Patel; David Henry; William J Harrington; Blossom A Damania; Dirk P Dittmer
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

9.  Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus.

Authors:  Ling Wang; Dirk P Dittmer; Christine C Tomlinson; Farnaz D Fakhari; Blossom Damania
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

10.  EVpedia: an integrated database of high-throughput data for systemic analyses of extracellular vesicles.

Authors:  Dae-Kyum Kim; Byeongsoo Kang; Oh Youn Kim; Dong-Sic Choi; Jaewook Lee; Sae Rom Kim; Gyeongyun Go; Yae Jin Yoon; Ji Hyun Kim; Su Chul Jang; Kyong-Su Park; Eun-Jeong Choi; Kwang Pyo Kim; Dominic M Desiderio; Yoon-Keun Kim; Jan Lötvall; Daehee Hwang; Yong Song Gho
Journal:  J Extracell Vesicles       Date:  2013-03-19
View more
  111 in total

1.  Delivery of miR-155 to retinal pigment epithelial cells mediated by Burkitt's lymphoma exosomes.

Authors:  Changshin Yoon; Jayoung Kim; Gabin Park; Seonghan Kim; Daejin Kim; Dae Young Hur; Bomi Kim; Yeong Seok Kim
Journal:  Tumour Biol       Date:  2015-07-26

2.  Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells.

Authors:  Zhen Lin; Kenneth Swan; Xin Zhang; Subing Cao; Zoe Brett; Stacy Drury; Michael J Strong; Claire Fewell; Adriane Puetter; Xia Wang; MaryBeth Ferris; Deborah E Sullivan; Li Li; Erik K Flemington
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

3.  Human Cytomegalovirus UL135 and UL136 Genes Are Required for Postentry Tropism in Endothelial Cells.

Authors:  Farah Bughio; Mahadevaiah Umashankar; Jean Wilson; Felicia Goodrum
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  Oncogenic herpesviruses sending mixed signals.

Authors:  D Michiel Pegtel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-19       Impact factor: 11.205

5.  Transmembrane Domains Mediate Intra- and Extracellular Trafficking of Epstein-Barr Virus Latent Membrane Protein 1.

Authors:  Dingani Nkosi; Lauren A Howell; Mujeeb R Cheerathodi; Stephanie N Hurwitz; Deanna C Tremblay; Xia Liu; David G Meckes
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

Review 6.  Epstein-Barr virus in the pathogenesis of oral cancers.

Authors:  J T Guidry; C E Birdwell; R S Scott
Journal:  Oral Dis       Date:  2017-04-18       Impact factor: 3.511

Review 7.  Exosomes and other extracellular vesicles in host-pathogen interactions.

Authors:  Jeffrey S Schorey; Yong Cheng; Prachi P Singh; Victoria L Smith
Journal:  EMBO Rep       Date:  2014-12-08       Impact factor: 8.807

Review 8.  The Promise of Proteomics in the Study of Oncogenic Viruses.

Authors:  Alison A McBride
Journal:  Mol Cell Proteomics       Date:  2017-01-19       Impact factor: 5.911

9.  Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling.

Authors:  Danyang Gong; Xinghong Dai; Yuchen Xiao; Yushen Du; Travis J Chapa; Jeffrey R Johnson; Xinmin Li; Nevan J Krogan; Hongyu Deng; Ting-Ting Wu; Ren Sun
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 10.  Exosomes and their role in CNS viral infections.

Authors:  Gavin C Sampey; Shabana S Meyering; Mohammad Asad Zadeh; Mohammed Saifuddin; Ramin M Hakami; Fatah Kashanchi
Journal:  J Neurovirol       Date:  2014-02-28       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.